Placebo matching lenvatinib

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Nonsquamous Non-small Cell Lung Cancer

Phase 3

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

CompletedNCT03829319

Merck Sharp & Dohme LLCNonsquamous Non-small Cell Lung Cancer

Start: 2019-03-25End: 2024-08-30Updated: 2026-02-05

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

CompletedNCT04716933

Merck Sharp & Dohme LLCNonsquamous Non-small Cell Lung Cancer

Start: 2019-11-05End: 2024-08-30Updated: 2025-09-09

Related Papers

Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study

Journal of Thoracic Oncology2025-05-244 citations

64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study

Immuno-Oncology Technology2023-12-015 citations

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis

Frontiers in Oncology2022-01-149 citations

The LEAP Program: Lenvatinib Plus Pembrolizumab for the Treatment of Advanced Solid Tumors

Future Oncology2020-12-1078 citations

Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.

Journal of Clinical Oncology2019-05-207 citations